A linear decapeptide derived from cyclic peptide GS and its application
By designing and preparing the linear decapeptide Pf-10 derived from the cyclic peptide GS, the problems of erythrological toxicity, difficulty and cost of synthesis of GS are solved, and better biosafety and antibacterial activity are achieved, and it has the potential for clinical applications and large-scale production.
CN118530301BActive Publication Date: 2025-03-25ZUNYI MEDICAL UNIV ZHUHAI CAMPUS
2 Cites 0 Cited by
Patent Information
- Application Number
- CN202410125366.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2023-12-28
- Filing Date
- 2024-01-29
- Publication Date
- 2025-03-25
- Estimated Expiration
- 2044-01-29
AI Technical Summary
Technical Problem
Natural cyclic peptide GS faces the problems of erythrological toxicity, difficulty and high synthesis of erythrocytes in clinical application and development prospects, which limits its large-scale production and clinical application.
Method used
A linear decapeptide Pf-10 derived from cyclic peptide GS was designed, and prepared by polypeptide solid phase synthesis method, which improved the hemolytic toxicity and cytotoxicity of GS and reduced the preparation difficulty and cost.
Benefits of technology
The linear decapeptide Pf-10 significantly improved the biosafety of GS, maintained good antibacterial activity, showed strong antibacterial effects on Gram-positive and drug-resistant bacteria, and had the potential to be used to treat Aβ-related diseases.
✦ Generated by Eureka AI based on patent content.
Abstract
The present invention discloses a linear decapeptide derived from a cyclic peptide GS and its application. The present invention uses the natural antibacterial cyclic peptide GS as a lead active peptide, and designs a linear decapeptide Pf-10 through derivatization design. The linear decapeptide Pf-10 maintains the excellent antibacterial ability of the lead cyclic peptide GS well, and shows good antibacterial activity against clinically representative Gram-positive bacteria and drug-resistant bacteria. At the same time, the linear decapeptide Pf-10 of the present invention can effectively inhibit Aβ aggregation and promote the disaggregation of Aβ aggregates, and has the potential to be developed into a clinically used drug for treating Aβ-related diseases such as glaucoma, age-related macular degeneration and Alzheimer's disease.
Need to check novelty before this filing date? Find Prior Art